1-7 of 7
treatment resistant disorders
Close
Sort by
Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Clinical Trials & Observations
Naveen Pemmaraju, Bing Z. Carter, Prithviraj Bose, Nitin Jain, Tapan M. Kadia, Guillermo Garcia-Manero, Carlos E. Bueso-Ramos, Courtney D. DiNardo, Sharon Bledsoe, Naval G. Daver, Uday Popat, Marina Y. Konopleva, Lingsha Zhou, Sherry Pierce, Zeev E. Estrov, Gautam M. Borthakur, Maro Ohanian, Wei Qiao, Lucia Masarova, Xuemei Wang, Po Yee Mak, Jorge Cortes, Elias Jabbour, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3163–3173.
https://doi.org/10.1182/bloodadvances.2020003829
Published: 2021
Journal Articles

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

Clinical Trials & Observations
Flora Peyvandi, Spero Cataland, Marie Scully, Paul Coppo, Paul Knoebl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Jessica Minkue Mi Edou, Hilde De Winter, Filip Callewaert
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2137–2141.
https://doi.org/10.1182/bloodadvances.2020001834
Published: 2021
Includes: Supplemental data
Journal Articles

Unexpected redundancy of Gpr56 and Gpr97 during hematopoietic cell development and differentiation

Antonio Maglitto, Samanta A. Mariani, Emma de Pater, Carmen Rodriguez-Seoane, Chris S. Vink, Xianhua Piao, Mari-Liis Lukke, Elaine Dzierzak
Journal: Blood Advances
Blood Adv (2021) 5 (3): 829–842.
https://doi.org/10.1182/bloodadvances.2020003693
Published: 2021
Includes: Supplemental data
Journal Articles

Phase 1/2a study of 177 Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

Clinical Trials & Observations
Arne Kolstad, Tim Illidge, Nils Bolstad, Signe Spetalen, Ulf Madsbu, Caroline Stokke, Johan Blakkisrud, Ayca Løndalen, Noelle O'Rourke, Matthew Beasley, Wojciech Jurczak, Unn-Merete Fagerli, Michal Kaščák, Mike Bayne, Aleš Obr, Jostein Dahle, Lisa Rojkjaer, Veronique Pascal, Harald Holte
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4091–4101.
https://doi.org/10.1182/bloodadvances.2020002583
Published: 2020
Includes: Supplemental data
Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Clinical Trials & Observations
Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike
Journal: Blood Advances
Blood Adv (2020) 4 (4): 599–606.
https://doi.org/10.1182/bloodadvances.2019000795
Published: 2020
Includes: Supplemental data
Journal Articles

Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment

Quentin A. Hill, Anita Hill, Sigbjørn Berentsen
Journal: Blood Advances
Blood Adv (2019) 3 (12): 1897–1906.
https://doi.org/10.1182/bloodadvances.2019000036
Published: 2019
Includes: Supplemental data
Journal Articles

Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma

Reid W. Merryman, Philippe Armand, Kyle T. Wright, Scott J. Rodig
Journal: Blood Advances
Blood Adv (2017) 1 (26): 2643–2654.
https://doi.org/10.1182/bloodadvances.2017012534
Published: 2017